Here are the S-1 registration statements from LeonaBio, Inc. (LONA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow LONA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LONA filings page.
LeonaBio, Inc. is registering up to 5,502,402 shares of common stock for resale by Sermonix Pharmaceuticals, Inc., issuable upon exercise of a pre-funded warrant from a December 2025 licensing transaction. LeonaBio will not sell any shares in this offering and receives no resale proceeds.
The company will receive only the nominal cash exercise price of $0.001 per share, or about $5,502 in gross proceeds if the warrant is fully exercised. As of March 16, 2026, LeonaBio had 9,393,514 shares of common stock outstanding, and its stock traded at $8.42 per share on Nasdaq under the symbol “LONA.”
LeonaBio, Inc. is registering up to 58,464,567 shares of common stock for resale by existing investors under a Form S-1 converted from a prior Form S-3. These shares include stock already issued and shares issuable from pre-funded warrants and other warrants held by December 2025 private placement investors.
LeonaBio will not sell any shares in this offering and will not receive proceeds from selling stockholders’ resales. It may receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share, and approximately $146,249,987 from cash exercises of warrants on 23,031,494 underlying shares at $6.35 per share. As of March 16, 2026, 9,393,514 shares of common stock were outstanding, and the stock traded at $8.42 on Nasdaq under the symbol LONA.